GoodRx Holdings (GDRX) Revenue (2019 - 2026)

GoodRx Holdings has disclosed Revenue across 8 years of filings, most recently posting $194.0 million for Q1 2026.

• Revenue for Q1 2026 came in at $194.0 million, down 4.42% year-over-year; the trailing twelve-month figure through Mar 2026 was $787.9 million (down 1.19% YoY), and the FY2025 annual result was $796.9 million, up 0.57% from the prior year.
• Revenue came in at $194.0 million for Q1 2026 at GoodRx Holdings, roughly flat from $194.8 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $203.3 million in Q1 2022 to a low of $180.0 million in Q3 2023.
• The 5-year median for Revenue is $195.3 million (2024), against an average of $194.1 million.
• Peak annual rise in Revenue reached 26.74% in 2022, while the deepest fall reached 13.67% in 2022.
• GoodRx Holdings' Revenue stood at $184.1 million in 2022, then advanced by 6.81% to $196.6 million in 2023, then gained by 0.99% to $198.6 million in 2024, then declined by 1.91% to $194.8 million in 2025, then dropped by 0.4% to $194.0 million in 2026.
• The last three Revenue figures came in at $194.0 million (Q1 2026), $194.8 million (Q4 2025), and $196.0 million (Q3 2025), per Business Quant data.